10-Q: VivoSim Labs Faces Going Concern Warning Amid Strategic Shift

VivoSim Labs, Inc. reports substantial doubt about its ability to continue as a going concern, despite a strategic pivot to 3D human tissue models for drug testing and the sale of its FXR program.

Summary

• VivoSim Labs, Inc. (formerly Organovo Holdings, Inc.) has transitioned to a pharmaceutical and biotechnology services company, focusing on 3D human tissue models for liver and intestinal toxicology insights.
• The company sold its FXR program in March 2025 for $10.0 million, including $9.0 million at closing and $1.0 million in escrow, with potential future milestones of up to $50.0 million.
• The U.S. FDA's April 10, 2025 announcement to favor non-animal New Approach Methodologies (NAM) is anticipated to accelerate the adoption of human tissue models.
• VivoSim's liver toxicology platform demonstrated a 'world's best' predictive power with 87.5% sensitivity for challenging liver toxicity cases and 100% specificity.
• The Preclinical IBD Program is advancing, with a goal to submit an Investigational New Drug (IND) Application with the FDA by December 2026.
• The company reported a net loss of $2.545 million for the three months ended September 30, 2025, and $5.388 million for the six months ended September 30, 2025.
• Cash and cash equivalents decreased to $6.677 million as of September 30, 2025, from $11.312 million at March 31, 2025.
• Negative cash flow from operations for the six months ended September 30, 2025, was $6.318 million, an increase from $5.625 million in the prior year period.
• Management has concluded that substantial doubt exists about the company's ability to continue as a going concern for at least one year.
• The company's public float is less than $75.0 million, limiting its ability to raise capital through primary public offerings to one-third of its public float in any twelve-month period using shelf registration statements.
• A lawsuit from H.C. Wainwright & Co., LLC alleges breach of a tail financing provision, with the company counterclaiming for rescission, fraudulent inducement, and breach of contract.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the explicit 'going concern' warning, significant cash burn, substantial accumulated deficit, and the need for further capital raises under restrictive conditions. While the strategic shift and promising technology are positives, the immediate financial viability is severely challenged.

Positives

• The company has strategically pivoted to a pharmaceutical and biotechnology services model, focusing on 3D human tissue models for drug testing.
• The U.S. FDA's announcement on April 10, 2025, to refine animal testing requirements in favor of non-animal NAM methods is expected to accelerate market adoption for VivoSim's services.
• VivoSim's liver toxicology platform demonstrated best-in-class predictive power with 87.5% sensitivity for challenging liver toxicity cases and 100% specificity.
• The Preclinical IBD Program is progressing, with a goal to submit an IND Application with the FDA by December 2026.
• The sale of the FXR program in March 2025 generated $10.0 million upfront, with potential future milestone payments of up to $50.0 million.
• Research and development expenses decreased by 6% for the three months and 19% for the six months ended September 30, 2025, primarily due to reduced headcount.
• Interest income increased to $92,000 for the three months and $164,000 for the six months ended September 30, 2025, compared to prior year periods.

Negatives

• The company reported significant operating losses of $2.635 million for the three months and $5.550 million for the six months ended September 30, 2025.
• Cash and cash equivalents decreased by $4.635 million during the six months ended September 30, 2025, to $6.677 million.
• Net cash used in operating activities increased to $6.318 million for the six months ended September 30, 2025, from $5.625 million in the prior year.
• Working capital decreased to $5.2 million at September 30, 2025, from $8.4 million at March 31, 2025.
• The company has an accumulated deficit of $347.5 million as of September 30, 2025.
• Product revenue ceased, as the former Mosaic division ended commercial operations during the third quarter of fiscal 2025.
• The company is involved in a lawsuit with H.C. Wainwright & Co., LLC, seeking compensatory and consequential damages and attorneys' fees, with an accrual of $0.6 million for loss contingencies.
• The public float is less than $75.0 million, limiting capital raises through primary public offerings to one-third of the public float.
• The U.S. government shutdown and layoffs (starting October 1, 2025) could delay regulatory reviews and impact SEC operations, affecting the company's ability to access public markets.

Risks

• The company will incur substantial additional operating losses over the next several years as services and R&D activities proceed.
• Using the platform technology to develop human tissues and disease models for drug discovery and development is new and unproven.
• Requires access to a constant, steady, reliable supply of human cells to support services and R&D activities.
• May not be successful in retaining, acquiring, or in-licensing necessary rights to key technologies.
• Requires substantial additional funding, which would cause dilution to existing stockholders and may restrict operations or require relinquishing rights to technologies.
• Clinical drug development involves a lengthy and expensive process with uncertain timelines and outcomes, and earlier results may not be predictive of future results.
• The near and long-term viability of the services platform and R&D efforts depend on successfully establishing strategic relationships.
• Current and future legislation may increase the difficulty and cost of commercializing drug candidates and affect prices.
• Management has concluded that substantial doubt exists about the company's ability to continue as a going concern, which may hinder future financing.
• The company has a history of operating losses and expects to incur significant additional operating losses.
• There is no assurance that an active market in the common stock will continue at present levels or increase in the future.
• The price of the common stock may continue to be volatile, leading to investor losses and costly securities litigation.
• Patents covering products could be found invalid or unenforceable if challenged.
• Involvement in lawsuits to protect or enforce patents could be expensive, time-consuming, and unsuccessful.
• The business could be adversely impacted if unable to successfully attract, hire, and integrate key additional employees or contractors.
• Unstable market and economic conditions may have serious adverse consequences on the business, financial condition, and share price.
• Claims relating to improper handling, storage, or disposal of hazardous chemicals, biological materials, and infectious agents could be costly.
• Failure to obtain and sustain an adequate level of reimbursement for potential products by third-party payors would materially adversely affect future sales.
• Changes in government funding for the FDA, SEC, and other government agencies could hinder their ability to perform normal business functions.
• The anticipated benefits of the FXR program sale may not be fully realized if milestone payments are not received.
• Future strategic investments could negatively affect the business if desired returns are not achieved.
• The business could be adversely impacted if unable to retain executive officers and other key personnel.
• Subject to security breaches or other cybersecurity incidents that could compromise information and expose to liability.
• Compliance with global privacy and data security requirements could result in additional costs and liabilities.
• Conflicts of interest may arise with Viscient Biosciences, Inc. due to shared executive and board members.
• Failure to maintain the listing of common stock on the Nasdaq Capital Market could seriously harm liquidity and ability to raise capital.
• Investors may experience dilution of their ownership interests because of the future issuance of additional shares of capital stock.
• The company does not intend to pay dividends for the foreseeable future.
• Anti-takeover provisions in organizational documents and Delaware law may discourage or prevent a change of control.
• Inability to adequately prevent disclosure of trade secrets and other proprietary information.
• Claims that employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties.

Future Outlook

The company intends to focus on providing liver and intestinal toxicology insights using NAM models to pharmaceutical and biotech partners, aiming to reduce drug development risk and cost. It plans to advance its Preclinical IBD Program with a goal for an IND Application by December 2026. Management expects R&D expenses to decrease, and service revenue and cost of revenues to increase as the service model is executed. However, the company will require substantial additional funding to support future operating activities.

Management Comments

• Anticipate accelerated adoption of human tissue models following the U.S. FDA announcement on April 10, 2025, to refine animal testing requirements in favor of non-animal NAM methods.
• Our liver toxicology platform had a best-in-class predictive power, showing 87.5% sensitivity for challenging liver toxicity cases and 100% specificity.
• We continue to advance our Preclinical IBD Program, with the goal of having a product candidate ready for an Investigational New Drug (IND Application) with the FDA by December 2026.
• We expect our total operating expense for the fiscal year ending March 31, 2026, to be between $10 million and $12 million.
• We have concluded that the prevailing conditions and ongoing liquidity risks faced by us raise substantial doubt about our ability to continue as a going concern for at least one year.

Industry Context

The biotechnology and pharmaceutical industry is highly competitive and undergoing rapid technological change. The FDA's recent announcement favoring non-animal New Approach Methodologies (NAM) for drug testing represents a significant shift, potentially creating a favorable environment for companies like VivoSim Labs specializing in 3D human tissue models. This trend could reduce the high costs and risks associated with traditional animal testing and clinical trials, where less than 10% of drug candidates are approved. However, the industry also faces increasing scrutiny over drug pricing and evolving global privacy regulations, which could impact commercialization and operational costs.

Comparison to Industry Standards

• VivoSim's liver toxicology platform demonstrated a predictive power of 87.5% sensitivity for challenging liver toxicity cases, which is described as a 'world's best' in the filing.
• The platform also achieved 100% specificity, meaning no non-liver toxic compounds were incorrectly identified as toxic, which is a strong indicator of reliability compared to standard industry toxicology screens.

Corporate Governance

Legal Proceedings

• H.C. Wainwright & Co., LLC filed a complaint on August 27, 2024, alleging breach of a tail financing provision and seeking compensatory and consequential damages and attorneys' fees.
• The company filed an amended answer and counterclaimed on September 2, 2025, for rescission, fraudulent inducement, and breach of contract, seeking damages, interest, costs, and attorneys' fees.
• An accrual of $0.6 million has been recognized for loss contingencies associated with the H.C. Wainwright complaint, with $0.4 million in accrued expenses and $0.2 million as a liability to be settled in equity (warrants).

Related Party Transactions

• Intercompany agreement with Viscient Biosciences, Inc. (where Keith Murphy, Executive Chairman, is CEO and Chairman, and certain board members are investors) for 3D bioprinting technology services, shared facilities, and equipment. The company incurred $144,000 and $216,000 in R&D consulting expenses from Viscient for the three and six months ended September 30, 2025, respectively.
• Letter agreement with SternAegis Ventures through Aegis Capital Corp. (where Adam Stern, a board member, is Head of Private Equity Banking) to act as a non-exclusive financial advisor for 12 months, with fees contingent on certain transactions.

Stakeholder Impact

• Shareholders face significant dilution risk from potential future equity financings and the ongoing volatility of the common stock price.
• Employees may experience further headcount adjustments, as R&D staff decreased from 14 to 9 and SG&A staff from 5 to 4 on average.
• Customers and partners in the pharmaceutical and biotech industries stand to benefit from the company's advanced 3D human tissue models and toxicology insights, especially with the FDA's shift towards NAM methods.
• Creditors face increased risk due to the company's 'going concern' warning and substantial operating losses, which could impact the company's ability to meet its obligations.
• Regulatory bodies (FDA, SEC) are impacted by the company's compliance with evolving regulations and the potential for delays due to government shutdowns.

Next Steps

• Advance the Preclinical IBD Program with the goal of submitting an IND Application to the FDA by December 2026.
• Continue offering liver toxicology predictive screening and research services to pharmaceutical and biotech companies.
• Seek to raise additional capital through debt or equity financings or other financing arrangements to support future operating activities.
• Vigorously defend against the H.C. Wainwright & Co., LLC lawsuit and pursue counterclaims.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by the explicit 'going concern' warning from both management and auditors, significant cash burn from operations, and a rapidly dwindling cash balance. While the strategic pivot to 3D human tissue models and promising early data for its liver toxicology platform are positive, the execution risk for this unproven business model is high, and the need for substantial additional funding is critical. The current public float limitations on capital raises, coupled with ongoing litigation and the inherent volatility of the stock, present an unfavorable risk-reward profile for investors. The potential for significant dilution and the risk of Nasdaq delisting further underscore the precarious financial position, making a 'sell' recommendation prudent for seasoned investors.

Keywords

Biotechnology, Pharmaceutical Services, 3D Tissue Models, Liver Toxicology, Intestinal Toxicology, NAM Models, IBD, Drug Discovery, Preclinical Development, Going Concern, Capital Raise, SEC Filing, 10-Q, Intellectual Property, Corporate Governance, Nasdaq Listing